FDA OKs Trijardy for patients with type 2 diabetes, Eli Lilly says

Eli Lilly (NYSE:LLY) says the Food and Drug Administration approved its Trijardy XR tablet to help lower blood sugar in adults with type 2 diabetes.

Lilly says Trijardy combines three medicines – Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release – in one pill, which will be a once-a-day medication.

The FDA approval was based on two randomized open-label trials that assessed the bioequivalence of empagliflozin, linagliptin and metformin hydrochloride extended release fixed-dose combination tablets and their individual components in healthy adults.


Read More   Purplebricks left red faced as it pulls out of US property market 

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.